Lawsuits Against Pradaxa, Xarelto and Eliquis Growing As Deaths Mount
Lawsuits Against Pradaxa, Xarelto and Eliquis Growing As Deaths Mount
Misleading Publicity for Pradaxa, Xarelto, and Eliquis
For the last few years, the makers of Pradaxa, Xarelto and Eliquis have been battling for the lion’s share of a massive therapeutic drug market that the international news agency Reuters estimates to be “worth at least $10 billion a year.” Their TV commercials claim the new drugs are superior to Warfarin (Coumadin) because patients do not have to be tested frequently or be on a special diet.
Doctors also have been paid to make speeches to medical communities touting their advantages. The drugs’ manufacturers spent $19.4 million in five months in 2013 ”wooing physicians…by paying for meals, promotional speeches, consulting gigs and educational gifts…” according to the New York Times.
The claims are misleading. The new drugs must be closely monitored in certain cases. And the “special diet” necessary with Warfarin that the TV commercials stress as a deterrent, is simple — it eliminates foods with high amounts of Vitamin K, like spinach and broccoli.
For 30 years, Wayne Wright LLP has been successfully winning cases against companies that make misleading claims, exaggerate the benefits of their drugs and market them despite hidden, sometimes fatal side effects. Pradaxa’s “flaw” as the New York Times called it in 2012, is the fact that it has no antidote. The same flaw also applies to Xarelto and Eliquis. There is no medication to stop the bleeding once it starts in patients taking these drugs.
The Benefit of Warfarin
Warfarin has an antidote. It can stop bleeding. And doctors have been prescribing it for nearly 60 years to dissolve deep vein blood clots that can cause fatal strokes and heart attacks.
A patient on Pradaxa, Xarelto or Eliquis, who begins hemorrhaging from a gastric ulcer or after a minor fall, can easily bleed to death in a matter of hours. Patients with a history of kidney or gastric problems are among those with the greatest risk of dying on these anticoagulants. They must be monitored while taking these drugs.
Deaths Associated with Pradaxa, Xarelto, Eliquis
Stories about patients taking the new drugs who bled to death in emergency rooms began appearing shortly after Pradaxa was approved by the FDA. In 2011, a Houston doctor desperately tried to save an elderly man who came to his emergency room, walking and talking, after a minor fall. Within a few hours, he bled to death despite the doctor’s efforts to save him. The doctor also reported eight similar deaths in one year at his hospital.
In 2012, Salt Lake City doctors tried in vain to save an elderly man taking one of the new blood thinners. He died from a brain hemorrhage after a minor fall. The patient of a Pennsylvania doctor nearly died from “…a massive GI bleed from a gastric ulcer one month” after starting one of the new anticoagulants. A patient in Virginia suddenly died “…from a massive gastrointestinal bleed” a short time after he began taking Eliquis to treat his atrial fibrillation.
In 2012, The New York Times reported that 542 deaths were linked to Pradaxa after it had only been on the market for two years. According to the newspaper, relatives of Pradaxa’s victims, doctors and others in the medical community blamed the U.S. Food and Drug Administration (FDA) for approving Pradaxa “because it allowed a potentially dangerous drug to be sold without an option for reversing its effects.”
Doctors question Pradaxa, Xarelto and Eliquis
- When reporters asked Dr. Alan Jacobson, the director of Anti-Coagulation Services at the Veterans Administration (VA) healthcare system in Loma Linda, California about Pradaxa in 2012 he said: “…the bad news is you can kill a patient as easily with the new drug as you could with the old drug…,” adding that Pradaxa needs monitoring like Warfarin.
- Dr. Richard H. Schmidt, associate professor of neurosurgery at the University of Utah had this to say about Pradaxa in 2012: “The practical experience is that once hemorrhagic complications occur with this drug, it is much more likely to be catastrophic than with Coumadin.”
- Dr. Sanjay Kaul, a cardiologist at Cedars Mount-Sinai Medical Center in Los Angeles who served on independent panels advising the FDA about Pradaxa said that doctors were failing to ask patients about kidney problems and gastrointestinal bleeding before prescribing the drugs: “I have received a dozen phone calls from local colleagues in the last couple of months about bleeding on Pradaxa and have yet to find a single case where that bleeding was not related to improper use of the drug…”
- Dr. Kenneth Bauer, head of hematology for the Veterans Administration’s health system in Boston criticized the FDA for approving two of the new anticoagulants: “…the FDA never should have approved Pradaxa and Xarelto for patients with severe kidney dysfunction since such patients were excluded from large studies…”
- In 2015, David Newman, director of clinical research for emergency medicine at Icahn School of Medicine at Mount Sinai Hospital in New York criticized the FDA for approving the new blood thinners: “The current process for drug approval often means it takes years after a drug is approved before we can learn of its dangers… “
Lawsuits Targeting Pradaxa, Xarelto and Eliquis Continue to Mount
Since 2010, at least 8,000 deaths have been linked to Pradaxa, Xarelto and Eliquis and more than 58,000 people have reported a serious side effect according to the Milwaukee Journal Sentinel.
Multi-million dollar lawsuits against all the manufacturers of the new blood thinners are mounting. In 2014, Boehringer Ingelheim paid $650 million to settle 4,000 Pradaxa lawsuits. During that drug’s first year on the market, sales for the German drug manufacturer amounted to more than $1 billion.
Questions are arising about those who vouch for the drugs. An investigation into a new system for determining who should be taking an anticoagulant drug was developed by a British doctor with “extensive financial ties to companies that make or market the new drugs…,” according to the Milwaukee Journal Sentinel. It also reported that many of the doctors who wrote the guidelines for the new drugs and made recommendations that boosted their sales had financial ties to the companies that manufactured or marketed them.
When questions like these arise after a hemorrhagic death or a near fatal bleeding incident involving a patient taking Pradaxa, Xarelto and Eliquis an immediate call to Wayne Wright is the right call. Too many victims and survivors never knew they were at risk or that the drugs had no antidote. The general public has not been sufficiently warned about them and apparently many doctors are not entirely aware of their dangers.
Legal assistance for those who have been victimized is immediately available at Wayne Wright LLP. Contact our experienced dangerous drug lawyers for help today at 602-883-2929 or by completing a contact form for a free consultation.
Victims Of Transvaginal Mesh Winning in Court On February 6, 2018, the Fourth Circuit Court of Appeals in West Virginia upheld a jury verdict in four consolidated products liability cases that awarded $4 million to women who sued Boston Scientific Corporation for...read more
Drugged driver in Arizona endangers crowd at children’s hospital Phoenix Children’s Hospital welcomed more than 2,000 people walking with candles in honor of its young patients on the 9th of December 2017 in its Ignite Hope Walk. A Santa Claus on a fire truck led the...read more
Invokana: Diabetic drug has serious side effects, newly-reported threat When the U.S. Food and Drug Administration (FDA) approved Invokana in 2013, TV commercials hailed it as a real boon. Its manufacturer, Johnson & Johnson, claimed it was the first diabetic...read more